IL139586A0 - PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS - Google Patents

PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS

Info

Publication number: IL139586A0
Authority: IL; Israel
Prior art keywords: pyrrolo; pyrimidine compounds; pyrimidine; compounds
Prior art date: 1998-06-19

Application number

IL13958699A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-19

Filing date

1999-06-14

Publication date

2002-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26781018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL139586(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-06-14 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2002-02-10 Publication of IL139586A0 publication Critical patent/IL139586A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL13958699A 1998-06-19 1999-06-14 PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS IL139586A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8986698P	1998-06-19	1998-06-19
US10478798P	1998-10-19	1998-10-19
PCT/IB1999/001100 WO1999065908A1 (en)	1998-06-19	1999-06-14	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS

Publications (1)

Publication Number	Publication Date
IL139586A0 true IL139586A0 (en)	2002-02-10

Family

ID=26781018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13958699A IL139586A0 (en)	1998-06-19	1999-06-14	PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS

Country Status (41)

Country	Link
US (3)	US6610847B2 (xx)
EP (1)	EP1087970B1 (xx)
JP (3)	JP4666762B2 (xx)
KR (1)	KR100415791B1 (xx)
CN (1)	CN1128800C (xx)
AP (1)	AP1021A (xx)
AR (1)	AR016499A1 (xx)
AT (1)	ATE265458T1 (xx)
AU (1)	AU3951899A (xx)
BG (1)	BG65119B1 (xx)
BR (1)	BR9911365A (xx)
CA (1)	CA2335492C (xx)
CZ (1)	CZ20004727A3 (xx)
DE (1)	DE69916833T2 (xx)
DK (1)	DK1087970T3 (xx)
EA (1)	EA005852B1 (xx)
ES (1)	ES2219018T3 (xx)
FR (1)	FR14C0019I2 (xx)
GE (1)	GEP20074227B (xx)
GT (1)	GT199900090A (xx)
HK (1)	HK1036801A1 (xx)
HR (1)	HRP20000885B1 (xx)
HU (1)	HUP0102574A3 (xx)
ID (1)	ID26698A (xx)
IL (1)	IL139586A0 (xx)
MA (1)	MA26654A1 (xx)
MY (1)	MY125916A (xx)
NO (2)	NO318784B1 (xx)
NZ (1)	NZ518444A (xx)
OA (1)	OA11572A (xx)
PA (1)	PA8476001A1 (xx)
PE (1)	PE20000698A1 (xx)
PL (1)	PL198640B1 (xx)
PT (1)	PT1087970E (xx)
RS (1)	RS50087B (xx)
SA (1)	SA99200283B1 (xx)
SK (1)	SK286640B6 (xx)
TN (1)	TNSN99126A1 (xx)
TR (1)	TR200003719T2 (xx)
TW (1)	TW505646B (xx)
WO (1)	WO1999065908A1 (xx)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
OA11572A (en) *	1998-06-19	2004-07-01	Pfizer Prod Inc	PyrroloÄ2,3-düpyrimidine compounds.
UA72290C2 (uk)	1999-12-10	2005-02-15	Пфайзер Продактс Інк.	СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
DZ3359A1 (fr) *	2000-06-26	2002-01-03	Pfizer Prod Inc	DÉRIVÉS DE PYRROLO [2,3-d] PYRIMIDINE UTILES COMME AGENTS IMMUNOSUPPRESSEURS
WO2002024667A1 (en)	2000-09-20	2002-03-28	Merck Patent Gmbh	4-amino-quinazolines
US7067550B2 (en) *	2000-11-03	2006-06-27	Massachusetts Institute Of Technology	Treatments for neurotoxicity in Alzheimer's Disease
DE10063294A1 (de) *	2000-12-19	2002-07-04	Aventis Pharma Gmbh	Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP1363702A4 (en) *	2001-01-30	2007-08-22	Cytopia Pty Ltd	PROCESS FOR INHIBITING KINASES
YU63703A (sh)	2001-02-12	2006-05-25	F. Hoffmann-La Roche Ag.	6-supstituisani pirido-pirimidini
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
GB0115393D0 (en) *	2001-06-23	2001-08-15	Aventis Pharma Ltd	Chemical compounds
DK1401416T5 (da) *	2001-06-29	2007-03-19	Ab Science	Anvendelse af C-kit-inhibitorer til behandling af inflammatorisk tarmsygdom
DE60223063T2 (de)	2001-06-29	2008-07-17	Ab Science	C-kit inhibitoren
EP1471907B1 (en) *	2001-06-29	2008-07-16	AB Science	Use of c-kit inhibitors for treating autoimmune diseases
EP1401413B1 (en)	2001-06-29	2006-11-22	AB Science	Use of tyrosine kinase inhibitions for treating allergic diseases
DE60212627T2 (de)	2001-06-29	2007-06-14	Ab Science	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung von entzündlichen Krankheiten
US7323469B2 (en)	2001-08-07	2008-01-29	Novartis Ag	7H-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en)	2001-08-07	2001-10-03	Novartis Ag	Organic compounds
US7829566B2 (en)	2001-09-17	2010-11-09	Werner Mederski	4-amino-quinazolines
GT200200234A (es)	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
WO2003059913A1 (en)	2002-01-10	2003-07-24	Bayer Healthcare Ag	Roh-kinase inhibitors
US6924290B2 (en)	2002-01-23	2005-08-02	Bayer Pharmaceuticals Corporation	Rho-kinase inhibitors
CA2473910C (en)	2002-01-23	2011-03-15	Bayer Pharmaceuticals Corporation	Pyrimidine derivatives as rho-kinase inhibitors
GB0202679D0 (en) *	2002-02-05	2002-03-20	Glaxo Group Ltd	Novel compounds
EP1388541A1 (en) *	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
PL378246A1 (pl)	2002-11-26	2006-03-20	Pfizer Products Inc.	Sposób leczenia odrzucania przeszczepu
US7169918B2 (en) *	2003-10-27	2007-01-30	Genelabs Technologies, Inc.	Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
MXPA06005882A (es) *	2003-11-25	2006-06-27	Pfizer Prod Inc	Metodo de tratamiento de la aterosclerosis.
BRPI0509299A (pt) *	2004-03-30	2007-09-18	Taisho Pharmaceutical Co Ltd	composto ou um sal, hidrato, ou solvato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para a profilaxia ou o tratamento de doença, para reduzir ingestão de alimento de um indivìduo, para induzir saciedade em um indivìduo, para controlar ou reduzir ganho de peso em um indivìduo, para modular um receptor de mch em um indivìduo e para produzir uma composição farmacêutica
CA2571710A1 (en)	2004-06-24	2006-11-02	Nicholas Valiante	Small molecule immunopotentiators and assays for their detection
CA2572314A1 (en)	2004-06-29	2006-01-12	Christopher N. Farthing	Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
EP1797054A2 (en)	2004-08-02	2007-06-20	OSI Pharmaceuticals, Inc.	Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US7423043B2 (en) *	2005-02-18	2008-09-09	Lexicon Pharmaceuticals, Inc.	4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
PL1891066T3 (pl)	2005-05-13	2011-05-31	Irm Llc	Związki i kompozycje jako inhibitory kinazy białkowej
JP5071374B2 (ja)	2005-07-14	2012-11-14	アステラス製薬株式会社	ヘテロ環ヤヌスキナーゼ３阻害剤
EP2251341A1 (en)	2005-07-14	2010-11-17	Astellas Pharma Inc.	Heterocyclic Janus kinase 3 inhibitors
WO2007038215A1 (en)	2005-09-22	2007-04-05	Incyte Corporation	Tetracyclic inhibitors of janus kinases
CN101801971A (zh) *	2005-09-30	2010-08-11	沃泰克斯药物股份有限公司	可用作janus激酶抑制剂的脱氮嘌呤
HUE025173T2 (hu)	2005-12-13	2016-01-28	Incyte Corp	Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
BRPI0709699A2 (pt) *	2006-03-29	2011-07-26	Foldrx Pharmaceuticals Inc	inibiÇço da toxidez da alfa-sinucleina
EP2043655A2 (en)	2006-04-25	2009-04-08	Astex Therapeutics Limited	Purine and deazapurine derivatives as pharmaceutical compounds
CA2673038C (en)	2006-12-22	2015-12-15	Incyte Corporation	Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
MX2009007426A (es)	2007-01-12	2009-07-17	Astellas Pharma Inc	Compuesto de piridina condensado.
AR065901A1 (es) *	2007-04-02	2009-07-08	Palau Pharma Sa	Derivados de pirrolipirimidina
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
SI2740731T1 (sl)	2007-06-13	2016-07-29	Incyte Holdings Coroporation	Kristalinične soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopen tilpropannitrila
DE102007027800A1 (de)	2007-06-16	2008-12-18	Bayer Healthcare Ag	Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
CN102007504A (zh) *	2007-11-10	2011-04-06	兰德马克绘图国际公司，哈里伯顿公司	工作流程自动化、自适应和集成的系统及方法
US8921336B2 (en) *	2007-11-28	2014-12-30	Dana-Farber Cancer Institute, Inc.	Small molecule myristate inhibitors of BCR-ABL and methods of use
EP2247591A1 (en)	2008-02-06	2010-11-10	Novartis AG	Pyrrolo [2, 3-d]pyridines and use thereof as tyrosine kinase inhibitors
KR101261514B1 (ko) *	2008-02-25	2013-05-07	에프. 호프만-라 로슈 아게	피롤로피라진 키나아제 저해제
ES2602577T3 (es)	2008-03-11	2017-02-21	Incyte Holdings Corporation	Derivados de azetidina y ciclobutano como inhibidores de JAK
WO2009115084A2 (de) *	2008-03-20	2009-09-24	Schebo Biotech Ag	Neue pyrrolopyrimidin-derivate und deren verwendungen
US20110201599A1 (en) *	2008-07-03	2011-08-18	Exelixis, Inc.	CDK Modulators
EP2324020A2 (en) *	2008-08-01	2011-05-25	Biocryst Pharmaceuticals, Inc.	Piperidine derivatives as jak3 inhibitors
KR101335843B1 (ko)	2008-08-20	2013-12-02	조에티스 엘엘씨	피롤로[2,3-ｄ]피리미딘 화합물
US8385364B2 (en) *	2008-09-24	2013-02-26	Nec Laboratories America, Inc.	Distributed message-passing based resource allocation in wireless systems
WO2010123919A2 (en)	2009-04-20	2010-10-28	Auspex Pharmaceuticals, Llc	Piperidine inhibitors of janus kinase 3
BRPI1012159B1 (pt)	2009-05-22	2022-01-25	Incyte Holdings Corporation	Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
JP6172939B2 (ja)	2009-05-22	2017-08-02	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｊａｋ阻害薬としての３−［４−（７ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１ｈ−ピラゾール−１−イル］オクタン−またはヘプタン−ニトリル
EP2451813B1 (en)	2009-07-08	2014-10-01	Leo Pharma A/S	Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
TWI466885B (zh) *	2009-07-31	2015-01-01	Japan Tobacco Inc	含氮螺環化合物及其醫藥用途
TW201111385A (en) *	2009-08-27	2011-04-01	Biocryst Pharm Inc	Heterocyclic compounds as janus kinase inhibitors
US9249145B2 (en)	2009-09-01	2016-02-02	Incyte Holdings Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PT2486041E (pt)	2009-10-09	2013-11-14	Incyte Corp	Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo
WO2011045702A1 (en) *	2009-10-15	2011-04-21	Pfizer Inc.	Pyrrolo[2,3-d] pyrimidine compounds
JP5739446B2 (ja)	2009-12-18	2015-06-24	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジン化合物
JP2013518882A (ja)	2010-02-05	2013-05-23	ファイザー・インク	ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物
EP2360158A1 (en) *	2010-02-18	2011-08-24	Almirall, S.A.	Pyrazole derivatives as jak inhibitors
CN102985417B (zh)	2010-03-10	2015-01-28	因塞特公司	作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物
CN102985425A (zh) *	2010-07-09	2013-03-20	利奥制药有限公司	作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途
US8933085B2 (en)	2010-11-19	2015-01-13	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
EP2640725B1 (en)	2010-11-19	2015-01-07	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
AU2012204843A1 (en) *	2011-01-07	2013-05-02	Leo Pharma A/S	Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
AU2012219395B2 (en)	2011-02-18	2017-05-25	Incyte Corporation	mTOR/JAK inhibitor combination therapy
CN103547580B (zh)	2011-03-22	2016-12-07	阿迪维纳斯疗法有限公司	取代的稠合三环化合物、其组合物及医药用途
CN103502249A (zh) *	2011-05-17	2014-01-08	普林斯匹亚生物制药公司	作为酪氨酸激酶抑制剂的氮杂吲哚衍生物
EA201490042A1 (ru)	2011-06-20	2014-10-30	Инсайт Корпорейшн	Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
US9358229B2 (en)	2011-08-10	2016-06-07	Novartis Pharma Ag	JAK PI3K/mTOR combination therapy
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
CN104185420B (zh)	2011-11-30	2017-06-09	埃默里大学	用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
MX358679B (es) *	2011-12-21	2018-08-31	Jiangsu Hengrui Medicine Co	Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo.
US9193733B2 (en)	2012-05-18	2015-11-24	Incyte Holdings Corporation	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CA2873967A1 (en)	2012-05-21	2013-11-28	Bayer Pharma Aktiengesellschaft	Substituted benzothienopyrimidines
AU2013282869B2 (en) *	2012-06-29	2015-12-24	Pfizer Inc.	Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
JP6106746B2 (ja) *	2012-07-17	2017-04-05	グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙ（Ｎｏ．２）Ｌｉｍｉｔｅｄ	選択的アンドロゲン受容体調節剤としてのインドールカルボニトリル類
AU2013292547B2 (en) *	2012-07-20	2017-05-04	Zoetis Services Llc	Dosing regimen for Janus Kinase (JAK) inhibitors
TW201412740A (zh) *	2012-09-20	2014-04-01	Bayer Pharma AG	經取代之吡咯并嘧啶胺基苯并噻唑酮
IN2015DN02008A (xx)	2012-09-21	2015-08-14	Advinus Therapeutics Ltd
CN102936251A (zh) *	2012-11-05	2013-02-20	上海毕得医药科技有限公司	一种吡咯并[2,3-d]嘧啶衍生物的制备方法
TWI761825B (zh)	2012-11-15	2022-04-21	美商英塞特控股公司	盧梭利替尼之緩釋性劑型
KR101683061B1 (ko) *	2013-02-07	2016-12-07	한국과학기술연구원	ＪＡＫ-3 저해제로 유용한 ７Ｈ-피롤로[2,3-ｄ]피리미딘-4-싸이올 유도체
MA38347A1 (fr)	2013-02-22	2017-10-31	Pfizer	Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
EP2964650B1 (en)	2013-03-06	2018-12-05	Incyte Holdings Corporation	Processes and intermediates for making a jak inhibitor
US9650375B2 (en)	2013-03-14	2017-05-16	Merck Sharp & Dohme Corp.	Indole derivatives useful as anti-diabetic agents
IL277554B2 (en)	2013-08-07	2024-03-01	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
AU2014358792C1 (en)	2013-12-05	2021-08-26	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
US9695171B2 (en)	2013-12-17	2017-07-04	Pfizer Inc.	3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016024185A1 (en)	2014-08-12	2016-02-18	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US10703756B2 (en)	2015-05-01	2020-07-07	Pfizer Inc.	Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof
ES2822748T3 (es) *	2015-05-29	2021-05-04	Wuxi Fortune Pharmaceutical Co Ltd	Inhibidor de cinasa Janus
KR101771219B1 (ko)	2015-08-21	2017-09-05	양지화학 주식회사	야누스 키나제 1 선택적 억제제 및 그 의약 용도
AU2016322813B2 (en)	2015-09-14	2021-04-01	Pfizer Inc.	Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
CN106831779B (zh) *	2015-11-28	2019-07-19	南昌弘益药业有限公司	一类jak激酶抑制剂的新化合物
KR102124449B1 (ko)	2016-02-16	2020-06-26	조에티스 서비시즈 엘엘씨	7H-피롤로[2,3-d]피리미딘 화합물을 제조하기 위한 방법
CN107098908B (zh) *	2016-02-23	2021-01-08	欣凯医药科技(上海)有限公司	一种吡咯并嘧啶类化合物的制备方法和应用
EP3555074B1 (en)	2016-12-14	2022-07-27	Intervet International B.V.	Aminopyrazoles as selective janus kinase inhibitors
JP6944496B2 (ja)	2018-10-22	2021-10-06	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
JP2022506682A (ja) *	2018-11-05	2022-01-17	アビスタファーマソリューションズ，インコーポレーテッド	化合物
WO2020142557A1 (en)	2018-12-31	2020-07-09	Biomea Fusion, Llc	Irreversible inhibitors of menin-mll interaction
WO2020142559A1 (en) *	2018-12-31	2020-07-09	Biomea Fusion, Llc	Inhibitors of menin-mll interaction
NL2022471B1 (en)	2019-01-29	2020-08-18	Vationpharma B V	Solid state forms of oclacitinib
EP3946606B1 (en)	2019-03-27	2025-01-01	Insilico Medicine IP Limited	Bicyclic jak inhibitors and uses thereof
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
AU2021401834A1 (en)	2020-12-18	2023-07-06	Boehringer Ingelheim Animal Health USA Inc.	Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
US12018032B2 (en)	2021-08-20	2024-06-25	Biomea Fusion, Inc.	Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
WO2023029943A1 (zh) *	2021-09-03	2023-03-09	星药科技(北京)有限公司	一种芳杂环化合物及其制备方法和用途
US20250051337A1 (en) *	2021-09-28	2025-02-13	Sanford Burnham Prebys Medical Discovery Institute	Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
CN118541364A (zh)	2021-12-24	2024-08-23	英特维特国际股份有限公司	氨基吡唑化合物的用途
GB202215132D0 (en) *	2022-10-13	2022-11-30	Norwegian Univ Sci & Tech Ntnu	Compound
GB202215117D0 (en) *	2022-10-13	2022-11-30	Norwegian Univ Sci & Tech Ntnu	Compound
WO2024155719A1 (en)	2023-01-18	2024-07-25	Biomea Fusion, Inc.	Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3037980A (en) *	1955-08-18	1962-06-05	Burroughs Wellcome Co	Pyrrolopyrimidine vasodilators and method of making them
GB915303A (en)	1958-03-13	1963-01-09	Wellcome Found	Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof
US6136595A (en)	1993-07-29	2000-10-24	St. Jude Children's Research Hospital	Jak kinases and regulations of cytokine signal transduction
US5389509A (en)	1993-10-04	1995-02-14	Eastman Kodak Company	Ultrathin high chloride tabular grain emulsions
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de)	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JP3290666B2 (ja) *	1995-06-07	2002-06-10	ファイザー・インコーポレーテッド	複素環式の縮合環ピリミジン誘導体
JP4010563B2 (ja)	1995-07-05	2007-11-21	イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー	殺菌・殺カビ性のピリミジノン類
DK0836605T3 (da) *	1995-07-06	2002-05-13	Novartis Ag	Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
PL321296A1 (en)	1995-11-14	1997-12-08	Pharmacia & Upjohn Spa	Derivatives of aryl and heteroaryl purine
AU1441497A (en)	1996-01-23	1997-08-20	Novartis Ag	Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) *	1996-02-29	1996-05-01	Pharmacia Spa	4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (de)	1996-03-06	1997-09-12	Novartis Ag	7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
WO1997049706A1 (en)	1996-06-25	1997-12-31	Novartis Ag	SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
BR9710362A (pt)	1996-07-13	1999-08-17	Glaxo Group Ltd	Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
AU720429B2 (en) *	1996-08-23	2000-06-01	Novartis Ag	Substituted pyrrolopyrimidines and processes for their preparation
CN1237177A (zh) *	1996-11-27	1999-12-01	辉瑞大药厂	稠合的二环嘧啶衍生物
KR20000070751A (ko)	1997-02-05	2000-11-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
AU6568398A (en)	1997-03-24	1998-10-20	Pharmacia & Upjohn Company	Method for identifying inhibitors of jak2/cytokine receptor binding
US6080847A (en) *	1997-12-04	2000-06-27	Incyte Pharmaceuticals, Inc.	Proteins associated with cell proliferation
EP1068206A1 (en)	1998-04-02	2001-01-17	Neurogen Corporation	Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors
MXPA00011773A (es)	1998-05-28	2002-06-04	Parker Hughes Inst	Quinazolinas para tratar tumores en el cerebro.
OA11572A (en) *	1998-06-19	2004-07-01	Pfizer Prod Inc	PyrroloÄ2,3-düpyrimidine compounds.
WO2000000202A1 (en)	1998-06-30	2000-01-06	Parker Hughes Institute	Method for inhibiting c-jun expression using jak-3 inhibitors
EP1105378B1 (en)	1998-08-21	2005-03-30	Parker Hughes Institute	Quinazoline derivatives
US6080747A (en)	1999-03-05	2000-06-27	Hughes Institute	JAK-3 inhibitors for treating allergic disorders
UA72290C2 (uk) *	1999-12-10	2005-02-15	Пфайзер Продактс Інк.	СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
DZ3359A1 (fr) *	2000-06-26	2002-01-03	Pfizer Prod Inc	DÉRIVÉS DE PYRROLO [2,3-d] PYRIMIDINE UTILES COMME AGENTS IMMUNOSUPPRESSEURS
AU2009100870A4 (en)	2008-10-01	2009-10-22	Rock Tone Enterprise Co., Ltd.	Drive mechanism for dehydrator
TWM358618U (en)	2008-12-26	2009-06-11	Rock Tone Entpr Co Ltd	Combination structure of mop holder and cleaning body

1999
- 1999-06-14 OA OA1200000349A patent/OA11572A/en unknown
- 1999-06-14 KR KR10-2000-7014402A patent/KR100415791B1/ko not_active IP Right Cessation
- 1999-06-14 TR TR2000/03719T patent/TR200003719T2/xx unknown
- 1999-06-14 DE DE69916833T patent/DE69916833T2/de not_active Expired - Lifetime
- 1999-06-14 AU AU39518/99A patent/AU3951899A/en not_active Abandoned
- 1999-06-14 PT PT99922454T patent/PT1087970E/pt unknown
- 1999-06-14 WO PCT/IB1999/001100 patent/WO1999065908A1/en active IP Right Grant
- 1999-06-14 PL PL345123A patent/PL198640B1/pl unknown
- 1999-06-14 CA CA002335492A patent/CA2335492C/en not_active Expired - Lifetime
- 1999-06-14 ES ES99922454T patent/ES2219018T3/es not_active Expired - Lifetime
- 1999-06-14 DK DK99922454T patent/DK1087970T3/da active
- 1999-06-14 JP JP2000554733A patent/JP4666762B2/ja not_active Expired - Lifetime
- 1999-06-14 SK SK1898-2000A patent/SK286640B6/sk not_active IP Right Cessation
- 1999-06-14 CN CN99807521A patent/CN1128800C/zh not_active Ceased
- 1999-06-14 RS YUP-785/00A patent/RS50087B/sr unknown
- 1999-06-14 AT AT99922454T patent/ATE265458T1/de not_active IP Right Cessation
- 1999-06-14 EP EP99922454A patent/EP1087970B1/en not_active Expired - Lifetime
- 1999-06-14 CZ CZ20004727A patent/CZ20004727A3/cs unknown
- 1999-06-14 IL IL13958699A patent/IL139586A0/xx active Protection Beyond IP Right Term
- 1999-06-14 HU HU0102574A patent/HUP0102574A3/hu unknown
- 1999-06-14 EA EA200001203A patent/EA005852B1/ru not_active IP Right Cessation
- 1999-06-14 TW TW088109926A patent/TW505646B/zh active
- 1999-06-14 ID IDW20002644A patent/ID26698A/id unknown
- 1999-06-14 BR BR9911365-1A patent/BR9911365A/pt not_active Application Discontinuation
- 1999-06-16 PA PA19998476001A patent/PA8476001A1/es unknown
- 1999-06-16 MA MA25630A patent/MA26654A1/fr unknown
- 1999-06-16 PE PE1999000531A patent/PE20000698A1/es not_active Application Discontinuation
- 1999-06-16 TN TNTNSN99126A patent/TNSN99126A1/fr unknown
- 1999-06-17 AR ARP990102916A patent/AR016499A1/es active IP Right Grant
- 1999-06-17 MY MYPI99002502A patent/MY125916A/en unknown
- 1999-06-17 AP APAP/P/1999/001584A patent/AP1021A/en active
- 1999-06-18 GT GT199900090A patent/GT199900090A/es unknown
- 1999-06-28 SA SA99200283A patent/SA99200283B1/ar unknown
2000
- 2000-11-08 NZ NZ518444A patent/NZ518444A/en not_active Application Discontinuation
- 2000-12-18 NO NO20006453A patent/NO318784B1/no not_active IP Right Cessation
- 2000-12-19 HR HR20000885A patent/HRP20000885B1/xx not_active IP Right Cessation
2001
- 2001-01-08 BG BG105129A patent/BG65119B1/bg unknown
- 2001-09-19 US US09/956,645 patent/US6610847B2/en not_active Expired - Lifetime
- 2001-11-06 HK HK01107744A patent/HK1036801A1/xx not_active IP Right Cessation
2003
- 2003-05-20 US US10/442,807 patent/US6890929B2/en not_active Expired - Lifetime
2005
- 2005-02-23 US US11/064,873 patent/US7687507B2/en not_active Expired - Fee Related
2007
- 2007-04-25 GE GEAP200710007A patent/GEP20074227B/en unknown
- 2007-08-06 JP JP2007204429A patent/JP4971068B2/ja not_active Expired - Lifetime
2011
- 2011-11-11 JP JP2011247593A patent/JP2012041365A/ja active Pending
2014
- 2014-03-07 FR FR14C0019C patent/FR14C0019I2/fr active Active
- 2014-05-13 NO NO2014012C patent/NO2014012I1/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO2014012I1 (no)	2014-06-02
BR9911365A (pt)	2001-03-13
SK18982000A3 (sk)	2002-08-06
KR20010053004A (ko)	2001-06-25
GT199900090A (es)	2000-12-09
JP2002518393A (ja)	2002-06-25
HRP20000885B1 (en)	2007-03-31
US6610847B2 (en)	2003-08-26
AP9901584A0 (en)	1999-06-30
HRP20000885A2 (en)	2001-10-31
US20030212273A1 (en)	2003-11-13
EA200001203A1 (ru)	2001-06-25
AR016499A1 (es)	2001-07-04
DE69916833T2 (de)	2005-04-14
NO20006453L (no)	2001-02-05
MY125916A (en)	2006-08-30
JP4666762B2 (ja)	2011-04-06
US20050171128A1 (en)	2005-08-04
BG105129A (en)	2001-11-30
MA26654A1 (fr)	2004-12-20
AP1021A (en)	2001-11-09
RS50087B (sr)	2009-01-22
TW505646B (en)	2002-10-11
PE20000698A1 (es)	2000-08-19
CZ20004727A3 (cs)	2002-03-13
CN1305480A (zh)	2001-07-25
US20020019526A1 (en)	2002-02-14
OA11572A (en)	2004-07-01
FR14C0019I2 (fr)	2015-01-02
AU3951899A (en)	2000-01-05
EP1087970A1 (en)	2001-04-04
JP4971068B2 (ja)	2012-07-11
KR100415791B1 (ko)	2004-01-24
FR14C0019I1 (xx)	2014-04-11
HUP0102574A3 (en)	2002-01-28
US6890929B2 (en)	2005-05-10
EA005852B1 (ru)	2005-06-30
CA2335492A1 (en)	1999-12-23
JP2012041365A (ja)	2012-03-01
ID26698A (id)	2001-02-01
PT1087970E (pt)	2004-06-30
BG65119B1 (bg)	2007-03-30
NO318784B1 (no)	2005-05-09
HUP0102574A2 (hu)	2001-11-28
ES2219018T3 (es)	2004-11-16
CA2335492C (en)	2005-05-17
WO1999065908A1 (en)	1999-12-23
DE69916833D1 (de)	2004-06-03
CN1128800C (zh)	2003-11-26
TR200003719T2 (tr)	2001-03-21
HK1036801A1 (en)	2002-01-18
YU78500A (sh)	2003-04-30
PA8476001A1 (es)	2003-09-05
EP1087970B1 (en)	2004-04-28
US7687507B2 (en)	2010-03-30
NZ518444A (en)	2004-04-30
PL198640B1 (pl)	2008-07-31
SA99200283B1 (ar)	2006-03-25
SK286640B6 (sk)	2009-03-05
DK1087970T3 (da)	2004-08-02
TNSN99126A1 (fr)	2005-11-10
JP2007284455A (ja)	2007-11-01
PL345123A1 (en)	2001-12-03
GEP20074227B (en)	2007-10-25
NO20006453D0 (no)	2000-12-18
ATE265458T1 (de)	2004-05-15

Publication	Publication Date	Title
IL139598A0 (en)	2002-02-10	PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS
AP9901584A0 (en)	1999-06-30	Pyrrolo[2,3-d] pyrimidine compounds
EG24399A (en)	2009-04-29	Pyrrolo[2,3-D]pyrimidine compounds
IL149026A0 (en)	2002-11-10	PYRAZOLO [4, 3-d] PYRIMIDINE DERIVATIVES
CZ20011962A3 (cs)	2001-11-14	Nové triazolo[4,5-d]pyrimidinové sloučeniny
IL147908A0 (en)	2002-08-14	PYRROLO[2,3-d] PYRIMIDINE NUCLEOSIDE ANALOGS
IL137812A0 (en)	2001-10-31	Novel triazolo (4,5-d) pyrimidine compounds
PL353366A1 (en)	2003-11-17	Pyrazolo[4,3-d]pyrimidines
ZA982912B (en)	1998-10-09	6,7-disubstituted-4-aminopyrido [2,3-d] pyrimidine compounds
PL336265A1 (en)	2000-06-19	5,6,7-trisubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
SI1087970T1 (en)	2004-10-31	PYRROLO 2,3-d)PYRIMIDINE COMPOUNDS
ZA994004B (en)	2000-12-18	Pyrrolo[2,3-d]pyrimidine compounds.
SI1210349T1 (en)	2003-06-30	PYRAZOLO 4,3-d)PYRIMIDINES
ZA200202763B (en)	2003-06-25	Pyrazolo [4,3-D] pyrimidine derivatives.

Legal Events

Date	Code	Title	Description
2011-02-28	FF	Patent granted
2011-04-28	KB	Patent renewed
2013-06-27	KB	Patent renewed
2017-03-30	EXTF	Application for patent extension filed	Filing date: 20170222
2017-05-29	PEL	Intention of commissioner to extend period of protection	Free format text: PRODUCT NAME: OCLACITINIB MALEATE Extension date: 20240613
2017-06-29	KB	Patent renewed
2018-05-31	PEL	Intention of commissioner to extend period of protection	Free format text: PRODUCT NAME: OCLACITINIB MALEATE Extension date: 20220728
2018-10-31	EXTG	Extension of patent term granted	Extension date: 20220728